(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 December 2005 (29.12.2005)

PCT

(10) International Publication Number
WO 2005/123732 A1

(51) International Patent Classification[7]: C07D 471/04, A61K 31/439, A61P 25/00

(21) International Application Number: PCT/EP2005/006566

(22) International Filing Date: 17 June 2005 (17.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/581,020 18 June 2004 (18.06.2004) US

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Viena (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FEUERBACH, Dominik** [DE/DE]; Wehrgasse 3, 79379 Müllheim (DE). **MÜLLER, Werner** [CH/CH]; Sonnenweg 34A, CH-3073 Gümligen (CH). **ROY, Bernard, Lucien** [CH/CH]; Route de La Broye 10, CH-1700 Fribourg (CH). **TROXLER, Thomas, J.** [CH/CH]; Sennweg 27, CH-4246 Wahlen b. Laufen (CH). **HURTH, Konstanze** [DE/FR]; 4, Rue de l'Ancien Golf, F-68300 Saint Louis (FR). **FREDERIKSEN, Mathias** [NO/CH]; Pfeffingerstrasse 18, CH-4053 Basel (CH).


(74) Agent: **HILLEBRAND, Dirk**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]


(54) Title: 1-AZA-BICYCLO[3.3.1]NONANES




(I)



(I)





free base or acid addition salt form.

(57) Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or $N(R^1)$; Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C_5- C_{10aryl}, substituted or unsubstituted hetero-C_5-C_{10}aryl, a group $N(R^1)(R^4)$, or a group $N(R^2)(CHP^3R^4)$; R represent a hydrogen, C_1-C_4alkyl, or CF_3; R^2 represents hydrogen, C_1-C_4alkyl, or CF_3; R^3 represents hydrogen, C_1-C_4alkyl, or CF_3; R^4 represents a substituted or unsubstituted C_5-C_{10} aryl or a substituted or unsubstituted C_5-C_{10}heteroaryl; in

WO 2005/123732 A1

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.